This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 25% and 6.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Lags Q4 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -16.67% and 5.14%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 40% and 2.76%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0.61% and 0.51%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -40% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -80% and 1.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)
by Zacks Equity Research
Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround
by Zacks Equity Research
Cerus (CERS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Cerus (CERS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cerus (CERS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See an 89% Upside in Cerus (CERS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 88.6% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Cerus (CERS) Have the Potential to Rally 88% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Cerus (CERS) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Cerus (CERS) Have the Potential to Rally 89% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Cerus (CERS) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Cerus (CERS) Have the Potential to Rally 90% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
4 Growth Stocks Under $10 to Buy for 2022
by Sumit Singh
Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow.
How Much Upside is Left in Cerus (CERS)? Wall Street Analysts Think 44%
by Zacks Equity Research
The consensus price target hints at a 43.9% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
by Debanjana Dey
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Wall Street Analysts Think Cerus (CERS) Could Surge 35%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?